Eli Lilly is betting on a pediatric expansion to give it’s IL-23p19 inhibitor Omvoh an edge in the fiercely competitive ...

Novo has long sold a separate version of oral semaglutide for diabetes under the brand name Rybelsus, which the medicine ...

In the fiercely competitive inflammatory bowel disease (IBD) market, Eli Lilly is making the case for its antibody Omvoh as a ...

With a yearslong patent dispute between the two drugmakers finally put to bed—complete with a hefty settlement payout—United ...

Central to the new report (PDF) are the JEC Democrats' findings that Trump increased his stock holdings in the pharmaceutical ...

Hot off a pair of key FDA green lights this summer, rare disease specialist Ultragenyx has wasted little time cashing in a ...

As the momentum continues to pick up at NorthStar Medical Technologies, the radioisotope producer is strengthening ties in ...

The evolution of AI in clinical development is increasingly a story of action, not only insight. Predictive models helped ...

In this week's episode of "The Top Line," we're looking at two companies building on recent successes and pursuing new ...

Sanofi has avoided a European Union fine after antitrust regulators accepted its commitments to address the alleged ...

U.S.-based generic drugmaker Par Health has issued a voluntary recall of 22 lots of the direct thrombin inhibitor argatroban ...

Following a bumpy regulatory road that involved a refusal-to-file, ImmunityBio has won FDA approval to expand Anktiva into ...